Impaired blood glucose levels in patients with dyslipidemia: what are the therapeutic implications? The PREVENDIAB study

Future Cardiol. 2019 May;15(3):175-182. doi: 10.2217/fca-2018-0063. Epub 2019 Apr 5.

Abstract

Aim: Dyslipidemia and diabetes are two of the main cardiovascular risk factors due to their impact and high prevalence. The aim of this study was to analyze the prevalence of impaired glucose metabolism in dyslipidemic patients attending the cardiology department. Patients & methods: This was a multicenter, cross-sectional, observational epidemiological study that consecutively enrolled the first ten dyslipidemic patients who attended the cardiology outpatient clinic. To find associated factors between variables, a bivariate analysis was performed, using a Student's t-test and a Fisher's exact test. Results: From the 490 analyzed patients, 67.4% of them presented impaired blood glucose levels, 39.2% with DM and 28.1% with prediabetes. Conclusion: More than half of the patients presented alterations of the glucose metabolism, very few reached a good metabolic control and a great number were found polymedicated.

Keywords: dyslipidemia; impaired blood glucose levels; pitavastatin.

Publication types

  • Multicenter Study
  • Observational Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Blood Glucose / metabolism*
  • Cross-Sectional Studies
  • Dyslipidemias / blood*
  • Dyslipidemias / drug therapy
  • Dyslipidemias / epidemiology
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Male
  • Middle Aged
  • Prevalence
  • Quinolines / therapeutic use*
  • Risk Factors
  • Spain / epidemiology
  • Treatment Outcome

Substances

  • Blood Glucose
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Quinolines
  • pitavastatin